References in periodicals archive ?
0%) 2 (100%) 0 0 aeruginosa (n = 2) OFX = ofloxacin, CN = gentamicin, CAZ = ceftazidime, AUG = amoxicillin-clavulanate, CXM = cefuroxime.
Ceftazidime, methicillin, ampicillin, amoxicillin, cloxacillin, penicillin G (benzylpenicillin), penicillinase ([beta]-lactamase) and clavulanic acid were obtained from Sigma (Sigma-Aldrich, UK).
The results of antibiotic susceptibility tests indicated that all nine isolates in the study were resistant to cefotaxime and ciprofloxacin and intermediate or resistant to ceftazidime (Table II).
Elisabeth Bjork, Vice President, Global Medicines Development, AstraZeneca, said: "These positive results show the efficacy of CAZ-AVI in treating complicated urinary tract infections, including those resistant to ceftazidime, and further support regulatory submissions to make this medicine available to patients.
Two months earlier in Thailand, he had received treatment for hepatosplenic melioidosis with ceftazidime (120 mg/kg/d), TMP/SMX (10/50 mg/kg/d), and doxycycline (200 mg/d) for 15 days, and then oral amoxicillin/clavulanic acid (3 g/d) for 3 months.
Minimum inhibitory concentration (MIC) testing: MIC was determined by agar dilution methods for ceftazidime (0.
Forest will share with AstraZeneca, the costs of worldwide development of the ceftaroline and ceftazidime combinations with NXL 104.
CTX-M-15 enhances hydrolytic activity against ceftazidime (5).
NXL104 in combination with the cephalosporin antibiotic ceftazidime (CAZ-104) is currently in two Phase II clinical trials in patients with complicated intra-abdominal infections (cIAIs) and patients with complicated urinary tract infections (cUTIs).
Ali these isolates were ceftazidime resistant and when tested by CAZ-MPA method, MBL production was seen in 97 (97%) of them.
AVYCAZ combines ceftazidime, a cephalosporin with in vitro activity against certain Gram-negative and Gram-positive bacteria, and avibactam, a non-beta-lactam beta-lactamase inhibitor that inactivates certain key beta-lactamases and protects ceftazidime from degradation by these beta-lactamases.
Treatment was considered appropriate if it contained ceftazidime, a carbapenem, or amoxicillin/clavulanic acid with or without SMX/TMP.